Trial Profile

Phase IIb confirmatory trial of Zofin

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 09 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zofin (Primary)
Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use

Most Recent Events

04 Mar 2024 According to a ZEO ScientifiX, Inc media release, company name changed from Organicell to ZEO ScientifiX.
01 Jan 2021 New trial record
29 Dec 2020 According to an Organicell media release, subject to favorable results from phase I/II trial, careful data analysis, discussion with and approvals from the FDA, the company expects to initiate this trial as early as the first quarter of 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com